These findings indicate that miR-32 may serve as a tumor gene in breast cancer, at least partly via directly targeting FBXW7, and may therefore act as a potential candidate for miRNA-based therapy against breast cancer. This evidence concerns the gene FBXW7 and breast carcinoma.